$SKYH

Gonzalez Francisco purchased $36K of SKYH

Gonzalez Francisco (Chief Financial Officer) purchased 3,850 shares of Sky Harbour Group Corp (SKYH) at $9.25 on 2026-10-02.

Original reporting
SEC EDGAR · Gonzalez Francisco
Published Oct 5, 2026, 1:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 1:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SKYH
Neutral
high confidence
Mentioned
$SKYH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SKYHNeutralLow
01

Why it matters

The CFO's purchase modestly raises his ownership, but the transaction size is too small to move the stock significantly.

02

Market read

Primary insider purchase disclosure with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 4/10Novelty 4/10Timing: today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$SKYHNeutralHigh confidence
Context

Form 4 shows CFO Gonzalez Francisco bought 3,850 shares for $35.6K, increasing his stake to 718,538 shares.

Expected impact

slight upward pressure as market prices in insider confidence

Evidence & confidence

The purchase is a primary disclosure but the amount is low relative to market cap, limiting impact.

Market effects

Minimal effect on the broader aerospace/defense sector.

No significant regional impact.

Limited to investors tracking insider activity.

Counterpoint

The purchase could be a routine portfolio rebalancing rather than a bullish signal.

Key entities

  • Sky Harbour Group Corp

    Issuer of the Form 4 filing.

  • Gonzalez Francisco

    Chief Financial Officer of Sky Harbour Group Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SKYHMed

Sky Harbour Targets EBITDA Inflection as Private Hangar Network Expands

Sky Harbour Group (NYSE:SKYH) expects to achieve EBITDA positivity by year-end, driven by its expanding network of private hangar campuses. The company operates eight campuses and has 23 ground leases, with four under construction. It aims to maintain development costs around $300 per square foot. Sky Harbour's debt includes a 2021 issuance at 4.18% and a 4.73% construction facility with JPMorgan. Lease rates at Miami Opa-locka averaged $41 per square foot in phase one and $51 in phase two.

$SKYHMedAI 8/10

Sky Harbour announces $40 million equity financing deal

Sky Harbour Group (SKYH) entered a stock purchase agreement for a registered direct offering of 4,000,000 Class A common shares at $10.00 each, closing Aug. 12, 2026, for $40 million gross proceeds for general corporate purposes. A 90-day lock-up was agreed. Boston Omaha arranged a concurrent secondary sale of 360,000 shares at $10.00, expected to close Aug. 14, 2026.

$SKYHMed

Sky Harbour Announces Q2 Results and Updates on Leasing, Construction, Funding and Other Activities Reaffirms Guidance for Year End 2026

Sky Harbour Group Corp (SKYH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sky Harbour Announces Q2 Results and Updates on Leasing, Construction, Funding and Other Activities Reaffirms Guidance for Year End 2026 WEST HARRISON, N.Y.--( BUSINESS WIRE )--Sky Harbour Group Corporation (NYSE: SKYH, SKYH WS) (“SHG” or the “Company”), an aviation

$SKYHMedAI 8/10

Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease

Skyhawk Therapeutics reported 12-month cUHDRS subcomponent results from its Phase 1/2 trial of oral Huntington’s disease candidate SKY-0515. Mean changes vs expected worsening (from Enroll-HD propensity-weighted analyses) were favorable for TFC (+0.07 vs -0.87), TMS (-2.00 vs 2.21), SDMT (-0.19 vs -1.78), and SWRT (+3.44 vs -3.13). CGI/PGI showed no assessed worsening and 65% of participants/50% of clinicians reported improvement; mHTT blood reductions up to 69% and PMS1 mRNA up to 26%.

$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).